Pegavision Corporation (6491.TW)
TWD 335.5
(-3.59%)
TWD 335.5
(-3.59%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.65 Billion TWD | 7.38% |
| 2022 | 1.54 Billion TWD | 23.51% |
| 2021 | 1.24 Billion TWD | 74.54% |
| 2020 | 715.35 Million TWD | 50.45% |
| 2019 | 475.49 Million TWD | -12.13% |
| 2018 | 541.15 Million TWD | 78.65% |
| 2017 | 302.9 Million TWD | 62.08% |
| 2016 | 186.89 Million TWD | 47.03% |
| 2015 | 127.11 Million TWD | 84.32% |
| 2014 | 68.96 Million TWD | 54.48% |
| 2013 | 44.64 Million TWD | 227.82% |
| 2012 | -34.92 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 509.84 Million TWD | -11.12% |
| 2024 Q2 | 474.66 Million TWD | -6.9% |
| 2024 Q3 | 437.77 Million TWD | -7.77% |
| 2023 Q1 | 338.4 Million TWD | -19.19% |
| 2023 Q3 | 377.97 Million TWD | 3.3% |
| 2023 Q2 | 365.89 Million TWD | 8.12% |
| 2023 Q4 | 573.63 Million TWD | 51.76% |
| 2023 FY | 1.65 Billion TWD | 7.38% |
| 2022 Q4 | 418.76 Million TWD | -0.63% |
| 2022 Q2 | 341.98 Million TWD | -4.99% |
| 2022 FY | 1.54 Billion TWD | 23.51% |
| 2022 Q1 | 359.96 Million TWD | -2.0% |
| 2022 Q3 | 421.41 Million TWD | 23.23% |
| 2021 Q1 | 224.59 Million TWD | -20.14% |
| 2021 FY | 1.24 Billion TWD | 74.54% |
| 2021 Q4 | 367.29 Million TWD | 1.61% |
| 2021 Q3 | 361.46 Million TWD | 22.44% |
| 2021 Q2 | 295.21 Million TWD | 31.44% |
| 2020 Q2 | 140.02 Million TWD | 53.52% |
| 2020 FY | 715.35 Million TWD | 50.45% |
| 2020 Q3 | 202.9 Million TWD | 44.9% |
| 2020 Q1 | 91.21 Million TWD | -48.61% |
| 2020 Q4 | 281.22 Million TWD | 38.6% |
| 2019 Q3 | 107.69 Million TWD | 23.89% |
| 2019 Q2 | 86.92 Million TWD | -15.93% |
| 2019 Q1 | 103.39 Million TWD | -31.67% |
| 2019 FY | 475.49 Million TWD | -12.13% |
| 2019 Q4 | 177.46 Million TWD | 64.79% |
| 2018 Q4 | 151.31 Million TWD | -15.95% |
| 2018 FY | 541.15 Million TWD | 78.65% |
| 2018 Q3 | 180.03 Million TWD | 49.6% |
| 2018 Q2 | 120.33 Million TWD | 14.71% |
| 2018 Q1 | 104.9 Million TWD | 23.43% |
| 2017 Q3 | 84.98 Million TWD | 27.87% |
| 2017 Q1 | 66.46 Million TWD | 17.02% |
| 2017 FY | 302.9 Million TWD | 62.08% |
| 2017 Q4 | 84.98 Million TWD | 0.0% |
| 2017 Q2 | 66.46 Million TWD | 0.0% |
| 2016 Q1 | 36.64 Million TWD | 4.8% |
| 2016 Q2 | 36.64 Million TWD | 0.0% |
| 2016 Q3 | 56.8 Million TWD | 55.0% |
| 2016 FY | 186.89 Million TWD | 47.03% |
| 2016 Q4 | 56.8 Million TWD | 0.0% |
| 2015 Q4 | 34.96 Million TWD | 0.0% |
| 2015 Q2 | 28.58 Million TWD | 0.0% |
| 2015 Q3 | 34.96 Million TWD | 22.32% |
| 2015 Q1 | 28.58 Million TWD | 7.95% |
| 2015 FY | 127.11 Million TWD | 84.32% |
| 2014 Q2 | 8 Million TWD | 0.0% |
| 2014 Q3 | 26.48 Million TWD | 231.01% |
| 2014 FY | 68.96 Million TWD | 54.48% |
| 2014 Q4 | 26.48 Million TWD | 0.0% |
| 2014 Q1 | 8 Million TWD | -1.17% |
| 2013 Q2 | 14.22 Million TWD | 0.0% |
| 2013 Q4 | 8.09 Million TWD | 0.0% |
| 2013 Q1 | 14.22 Million TWD | 0.0% |
| 2013 FY | 44.64 Million TWD | 227.82% |
| 2013 Q3 | 8.09 Million TWD | -43.1% |
| 2012 FY | -34.92 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 198.4 Million TWD | -734.59% |
| Maxigen Biotech Inc. | 165.82 Million TWD | -898.566% |
| SciVision Biotech Inc. | 177.9 Million TWD | -830.805% |
| Bionime Corporation | 6.2 Million TWD | -26569.383% |
| Visco Vision Inc. | 301.61 Million TWD | -449.015% |